BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31935596)

  • 1. Differentiation between ovarian metastasis from colorectal carcinoma and primary ovarian carcinoma: Evaluation of tumour markers and "mille-feuille sign" on computed tomography/magnetic resonance imaging.
    Kurokawa R; Nakai Y; Gonoi W; Mori H; Tsuruga T; Makise N; Ushiku T; Abe O
    Eur J Radiol; 2020 Mar; 124():108823. PubMed ID: 31935596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling the mille-feuille sign: a key to diagnosing ovarian carcinosarcoma in addition to ovarian metastasis from colorectal carcinoma on MRI.
    Watanabe Y; Matsuki M; Nakamata A; Masuoka S; Kikuchi T; Fujii H; Hamamoto K; Mori H; Fukushima N; Sakaguchi M; Todo S; Fujiwara H
    Abdom Radiol (NY); 2024 Jun; ():. PubMed ID: 38860998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer.
    Li M; Tan J; Zhang Y; Ai C; Wang H; Zhang H; Jin Y; Chen Y
    Abdom Radiol (NY); 2021 Jun; 46(6):2367-2375. PubMed ID: 32424610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel classification of ovarian metastases originating from colorectal cancer by radiological imaging and macroscopic appearance.
    Kato MK; Shida D; Yoneoka Y; Yoshida H; Miyasaka N; Kanemitsu Y; Kato T
    Int J Clin Oncol; 2020 Sep; 25(9):1663-1671. PubMed ID: 32494980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative discrimination of tumour stage in clear cell carcinoma of the ovary using computed tomography and magnetic resonance imaging.
    Joo HL; Shin YR; Rha SE; Park CS; Shim DJ; Kim K
    Eur J Radiol; 2018 Dec; 109():19-26. PubMed ID: 30527303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT and MRI findings of type I and type II epithelial ovarian cancer.
    Liu D; Zhang L; Indima N; Peng K; Li Q; Hua T; Tang G
    Eur J Radiol; 2017 May; 90():225-233. PubMed ID: 28583639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation between borderline and benign ovarian tumors: combined analysis of MRI with tumor markers for large cystic masses (≥5 cm).
    Park SY; Oh YT; Jung DC
    Acta Radiol; 2016 May; 57(5):633-9. PubMed ID: 26231948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole solid tumour volume histogram analysis of the apparent diffusion coefficient for differentiating high-grade from low-grade serous ovarian carcinoma: correlation with Ki-67 proliferation status.
    Li HM; Zhang R; Gu WY; Zhao SH; Lu N; Zhang GF; Peng WJ; Qiang JW
    Clin Radiol; 2019 Dec; 74(12):918-925. PubMed ID: 31471063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features of complex solid and multicystic ovarian lesions: proposed algorithm for differential diagnosis.
    Choi JI; Park SB; Han BH; Kim YH; Lee YH; Park HJ; Lee ES
    Clin Imaging; 2016; 40(1):46-56. PubMed ID: 26277385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
    Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
    Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
    Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.
    Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
    Cancer Imaging; 2016 Feb; 16():3. PubMed ID: 26873307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
    Judson K; McCormick C; Vang R; Yemelyanova AV; Wu LS; Bristow RE; Ronnett BM
    Int J Gynecol Pathol; 2008 Apr; 27(2):182-90. PubMed ID: 18317225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.